Plain-English translation of NCT05187182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new experimental medication, to see if it can help treat advanced stomach and esophageal cancers when combined with chemotherapy and other immunotherapy drugs. The study will first find the right dose of the medication, then test it in larger groups of patients to see if it is safe and effective. Researchers hope this combination may help people with these cancers live longer and healthier lives.
Currently, people with advanced stomach and esophageal cancers that cannot be surgically removed have limited treatment options and often don't survive very long. This medication is being tested because early research suggests it might work better when paired with existing chemotherapy and immunotherapy treatments to improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will take the new medication by mouth twice daily and receive chemotherapy and immunotherapy infusions every two weeks in 14-day cycles. The study has two phases: first, researchers will test different doses of the medication in a small group to find the safest dose, then larger groups will receive that dose to confirm it works. You will have regular blood tests, imaging scans, and doctor visits to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States